(Q40517199)

21 September 2017

title

Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient (English)

1 reference

21 September 2017

0 references

Ozden MG

1

1 reference

21 September 2017

Erel A

series ordinal

2

1 reference

21 September 2017

Erdem O

series ordinal

3

1 reference

21 September 2017

Oztas MO

series ordinal

4

1 reference

21 September 2017

publication date

1 January 2005

1 reference

Journal of the European Academy of Dermatology and Venereology

21 September 2017

published in

1 reference

21 September 2017

volume

19

1 reference

21 September 2017

issue

1

1 reference

21 September 2017

page(s)

112-113

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01086.X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01086.X

Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01086.X

Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2004.01086.X

10.1111/J.1468-3083.2004.01086.X

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference